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Abstract 
Statin use is associated with lower advanced prostate cancer risk. In addition to cholesterol-lowering, 
statins have systemic anti-inflammatory properties. However, their effect on histological prostate 
inflammation is not well understood, particularly among men at increased prostate cancer risk but with a 
negative prostate biopsy. We examined associations between serum lipid levels, statin use and 
histological prostate inflammation using data from 6,655 men with a negative baseline prostate biopsy in 
the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Statin use and lipid levels [total 
cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides] were assessed 
at baseline. Inflammation was assessed by central review. Logistic regression was used to examine the 
effect of lipids and statin use on presence and extent of chronic and acute prostate inflammation [none, 
moderate (<20%), severe (≥20% biopsy cores)]. Chronic and acute inflammation affected 77% and 15% 
of men, respectively. Men with high HDL (≥60 vs. <40 mg/dl) had reduced presence of acute 
inflammation (OR 0.79; 95%CI 0.63-0.99), and were less likely to have severe acute inflammation (OR 
0.66; 95%CI 0.45-0.97), but there were no other associations between lipids and inflammation. Statin 
users had reduced presence of chronic inflammation (OR 0.81; 95%CI 0.69-0.95), and were less likely to 
have severe chronic (OR 0.80; 95%CI 0.68-0.95) and severe acute inflammation (OR 0.73; 95%CI 0.53-
1.00), relative to non-users. Given the possible role for inflammation in prostate cancer, the inverse 
association between statins and prostate inflammation suggests a mechanism linking statins with lower 
advanced prostate cancer risk.  
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Introduction 
An increasing amount of epidemiologic and laboratory data support a role for statins in chemoprevention. 
Some of the strongest evidence comes from prostate cancer, where statin use is associated with reduced 
risk of advanced disease and lower prostate cancer-specific mortality [1]. Statins effectively lower serum 
cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-
limiting enzyme for cholesterol synthesis in the liver. High serum cholesterol drives tumor growth in 
mouse models of prostate cancer [2, 3], and results from epidemiologic studies show that high serum 
cholesterol is associated with increased risk of biochemical recurrence [4, 5] and elevated prostate cancer-
specific mortality [6-8]. Together, these findings support a role for cholesterol, and for cholesterol-
lowering interventions, in prostate cancer [9]. In addition to targeted cholesterol-lowering effects, statins 
may also have off-target effects on the prostate via non-cholesterol mediated mechanisms [1]. Results 
from clinical trials demonstrate that statins lower C-reactive protein (CRP) levels in the serum [10, 11] 
and reduce cytokine production by circulating lymphocytes [12] independent of their cholesterol-lowering 
effects, showing that statins lower systemic inflammation. Our group previously reported that statin users 
had less histological inflammation in their prostate tumors than non-users [13], suggesting that statins can 
also lower inflammation in the prostate tumor. However, no studies, to our knowledge, have examined the 
effect of statin use and serum lipid levels on prostate inflammation in men without prostate cancer.  
Histological evaluation of negative prostate biopsies from prostate cancer screening and prevention trials 
has revealed prostate inflammation in approximately 60% - 80% of asymptomatic men undergoing biopsy 
due to elevated PSA levels [14-16]. However, the factors contributing to prostate inflammation are largely 
unknown. Our group previously reported that smokers had higher levels of prostate inflammation [17], 
showing that lifestyle factors may influence prostate biology. In the present analysis, we evaluated 
associations between serum lipid levels, statin use and prostate inflammation in negative baseline prostate 
biopsies of men participating in the REduction by DUtasteride of Prostate Cancer Events (REDUCE) trial 
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[18]. We hypothesized that high serum cholesterol would be associated with increased prostate 
inflammation, while statin use would be associated with reduced prostate inflammation. 
 
Materials and Methods 
Study population 
The REduction by DUtasteride of prostate Cancer Events (REDUCE) is a four year, multicenter, double-
blind and placebo-controlled study, the details of which have been described previously [18]. Only 
baseline data prior to randomization were used for the present analysis. Briefly, men were eligible for the 
study if they were between 50 and 75 years of age, and had a serum PSA level of 2.5-10 ng/ml (if 50-60 
years of age) or 3-10 ng/ml (if 60-75 years of age). Eligibility criteria also required men to have a single, 
negative biopsy (6-12 cores) within 6 months before enrollment (independent of trial protocol). Baseline 
biopsies were centrally reviewed to confirm a negative prostate cancer diagnosis. Men were excluded if 
they had a history of prostate cancer, high-grade intraepithelial neoplasia, atypical small acinar 
proliferation, a prostate volume >80 ml, had undergone previous prostate surgery, or had an International 
Prostate Symptom Score ≥25 or ≥20 while receiving α-blockers for treatment of benign prostatic 
hyperplasia.  
Exposure assessment 
At baseline, a detailed medical history was obtained including smoking, medical comorbidities, 
medication use and alcohol use. Total serum cholesterol, LDL, HDL and triglyceride levels were 
measured by Quest Diagnostic (Van Nuys, California, USA) at baseline before randomization. The vast 
majority of lipid values were obtained from serum drawn in the fasting state (99.8%). Recommended cut 
points for normal, borderline and abnormal serum levels (all in mg/dl) of total cholesterol (<200, 200-
239, ≥240), low density lipoprotein (LDL; <130, 130-159, ≥160), high density lipoprotein (HDL; ≥60, 
40-59, <40) and triglycerides (<150, 150-199, ≥200) were implemented according to National Cholesterol 
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Education Program (NCEP)-Adult Treatment Panel (ATP) III guidelines [19]. Subjects reported all 
medications they were currently using at baseline, including lipid-lowering medications (statins, fibrates 
and ezetimibe). The majority of men reporting lipid-lowering medication use were statin users (n=1,229; 
91%). Among statin users, the majority of men reported lipophilic statin use (simvastatin, lovastatin, 
fluvastatin, or atorvastatin; n=1,066; 87%). As such, we had insufficient numbers to conduct analysis 
stratified by statin type (i.e. lipophilic vs. hydrophilic) or by type of lipid-lowering medication (i.e. statin 
vs. non-statin). Data for dose and duration of statin use were unavailable. Therefore, we treated statin use 
versus statin non-use at baseline as our exposure variable, regardless of non-statin lipid-lowering 
medication use. 
Outcome assessment 
The presence and extent of histologic prostatic inflammation was assessed by central review of baseline 
negative biopsies. Chronic inflammation consisted mainly of lymphocytes and variable number of plasma 
cells and macrophages. Acute inflammation consisted of neutrophils. We calculated the extent of chronic 
inflammation and acute inflammation by dividing the number of biopsy cores with chronic and acute 
inflammation, respectively, by the total number of biopsy cores. Percent chronic and acute inflammation 
were each subsequently categorized as none, moderate (>0% - <20% of biopsy cores), and severe (≥20% 
of biopsy cores). Cut points were selected to ensure sufficient numbers of participants in each category 
for analysis. 
Statistical analysis 
Of the 8,122 men included in the efficacy population, we excluded men with a baseline PSA <2.5 ng/ml 
or >10 ng/ml (n=112). We also excluded men with missing data for race (n=82), body mass index (BMI; 
n=127), smoking status (n=3), and serum lipid levels (n=1,143), resulting in n=6,655 men included in the 
present analysis. As shown in Supplementary Table 1, men excluded due to missing lipid levels were less 
likely to be white, less likely to be North American, and less likely to use statins and non-steroidal anti-
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inflammatory drugs (NSAIDs). However, age, BMI or diabetes status did not differ between groups, nor 
did alcohol use or smoking status. Men with and without lipid data had similar prevalence of chronic 
prostate inflammation, but men with missing lipid data were more likely to have acute prostate 
inflammation. 
Differences in baseline characteristics according to the presence of chronic and acute prostate 
inflammation and according to statin use were examined using Student’s t tests and χ2 tests for continuous 
and categorical variables, respectively, and Kruskal-Wallis tests for continuous variables not normally 
distributed.  
Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for 
associations between serum lipid levels (borderline or abnormal levels vs. normal levels), statin use (vs. 
non-use) and the presence and extent of chronic and acute prostate inflammation. All models were 
adjusted for age at baseline (continuous), race (white, non-white), geographic region (North America, 
Europe, other), BMI (continuous, log-transformed), smoking status (never, former, current), and NSAID 
use. Models examining associations between serum lipids and prostate inflammation produced similar 
findings whether or not we further adjusted for statin use, and thus, we chose to present findings adjusted 
for statin use. We also explored further adjusting models examining associations between statin use and 
prostate inflammation for serum lipid levels but this did not alter our findings and therefore these findings 
are not presented. In sensitivity analyses, we excluded men using any lipid-lowering medications (statins, 
fibrates, ezetimibe) from our analyses of associations between serum lipid levels and prostate 
inflammation. Finally, we explored excluding men using non-statin lipid-lowering medications (n=180) 
from our analysis of associations between statin use and inflammation but this produced similar findings 
and so these results are not presented.   
Statistical analysis was performed using Stata, version 13.0 (Stata Corp., College Station, TX, USA). 
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Results 
Demographic characteristics of men with and without histologic prostate inflammation 
Chronic and acute prostate inflammation was detected in negative baseline prostate biopsies from 5,151 
(77%) and 1,005 (15%) men enrolled in the REDUCE trial, respectively. Men with chronic prostate 
inflammation were older at the time of enrollment, less likely to be white, less likely to be European and 
less likely to report heavy alcohol use relative to those without chronic prostate inflammation (Table 1). 
Men with acute prostate inflammation were younger at the time of enrollment, less likely to be European 
and more likely to be current smokers than those without acute prostate inflammation. However, there 
were no differences in race or alcohol intake by acute inflammation status. Median BMI did not differ by 
either chronic or acute prostate inflammation status, and the prevalence of diabetes and NSAID use was 
similar in men with and without chronic and acute prostate inflammation (Table 1).  
Demographic characteristics of men according to statin use 
Of a total of 6,655 participants in this analysis, 1,217 (18%) were statin users (Table 2). Relative to non-
users, statin users were older at time of enrollment, more likely to be white, and more likely to be North 
American. Statin users also had higher BMI, and a higher prevalence of diabetes than non-users. Finally, 
statin users were more likely to also use NSAIDs, but less likely to be current smokers than non-users. 
The prevalence of alcohol use did not differ significantly by statin use (Table 2). 
Associations between serum lipid levels and prostate inflammation 
Serum lipid levels were not associated with either the presence or extent of chronic prostate inflammation 
(Table 3). Neither were serum levels of total cholesterol, LDL or triglycerides associated with the 
presence or extent of acute inflammation (Table 4). However, relative to men with low HDL levels (<40 
ng/ml), those with high HDL (≥60 ng/ml) were less likely to have acute prostate inflammation (ORany vs. 
none 0.79; 95% CI 0.63-0.99), although the trend across HDL categories did not reach statistical 
significance (p-trend=0.071). Men with high HDL were also less likely to have severe acute 
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inflammation, defined as the presence of acute inflammation in ≥20% of biopsy cores (ORsevere vs. none 0.66; 
95% CI 0.45-0.97; Table 4). Restricting our analyses to men who were not using any lipid-lowering 
medications produced similar findings (Supplementary Tables 2 and 3). 
Associations between statin use and prostate inflammation 
Relative to non-users, statin users were less likely to have chronic prostate inflammation (ORany vs. none 
0.81; 95% CI 0.69-0.95), and the magnitude of this association was similar regardless of the extent of 
chronic inflammation (ORmoderate vs. none 0.82; 95% CI 0.68-0.99 and ORsevere vs. none 0.80; 95% CI 0.68-0.95; 
Table 5). Although statin use was not associated with the presence of acute inflammation (ORany vs. none 
0.97; 95% CI 0.81-1.17), statin users were less likely to have severe acute inflammation than non-users 
(ORsevere vs. none 0.73; 95% CI 0.53-1.00; p=0.052), although this association was borderline significant. 
 
Discussion 
The prevalence of statin use has increased rapidly over the past few decades and these medications are 
currently used by almost 30% of US adults [20]. In addition to their targeted cholesterol-lowering 
properties, statins reduce systemic inflammation [10] and have also been associated with reduced 
inflammatory infiltrate in prostate tumors [13]. However, direct effects of statins on histological 
inflammation in the benign prostate have not been described. Using data from 6,655 men with a negative 
baseline prostate biopsy participating in the REDUCE trial, we report that statin use was associated with 
reduced presence and extent of chronic prostate inflammation and reduced extent of acute prostate 
inflammation. 
A state of chronic inflammation has been suggested to play a role in the development of many different 
cancer types, including prostate [21, 22]. However, the clinical significance of histological prostate 
inflammation remains controversial. Findings from the Prostate Cancer Prevention Trial (PCPT) showed 
that histological inflammation in benign prostate tissue was positively associated with concomitant co-
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existence of high grade prostate cancer [16], with similar results seen in another small US biopsy study 
[23]. In contrast, data from REDUCE showed that the presence of histological inflammation in benign 
prostate tissue was inversely associated with prostate cancer risk upon subsequent biopsy [14]. An inverse 
association between benign prostate inflammation and prostate cancer risk has also been reported by a 
number of other epidemiologic studies [15, 24-26]. With the exception of PCPT where histological 
inflammation was assessed in PSA-independent prostate biopsies, all other studies evaluated the presence 
of histological inflammation in PSA-driven prostate biopsies. Among men with an elevated PSA but a 
negative biopsy, the elevated PSA may be due either to prostate inflammation or to undetected prostate 
cancer. Thus, men with an elevated PSA that is caused by inflammation may be at lower risk for prostate 
cancer detection upon re-biopsy, compared to their counterparts with an elevated PSA caused by occult 
prostate cancer. Since benign prostate tissue is difficult to obtain in the absence of a PSA-driven biopsy, 
the true direction of this association will be difficult to resolve. Given the null association between statin 
use and risk of either total or high grade prostate cancer in REDUCE [27], the clinical implications of our 
observed inverse association between statin use and histological prostate inflammation cannot be 
determined by the present study, and require further investigation. 
Inflammation of benign prostate tissue is common, affecting 60-80% of men, but few lifestyle factors 
influencing prostate inflammation have been identified. Using REDUCE data, we previously reported a 
higher prevalence of histological prostate inflammation in current versus former or never smokers [17], 
and a case-control study nested in the placebo arm of the PCPT reported that serum fatty acid levels were 
linked with prostate inflammation [28], showing that diet and lifestyle factors can impact prostate 
inflammation. Statins reduce PSA levels [29, 30], and use of these medications has been inversely 
associated with benign prostatic enlargement and lower urinary tract symptoms [31, 32], suggesting that 
statins also directly influence prostate biology. Inflammation has been suggested as one potential 
mechanism contributing to these effects [33-35]. Indeed, results from clinical trials have shown that 
statins have systemic anti-inflammatory properties over and above their cholesterol-lowering function 
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[10, 11], and studies have also shown tissue-specific anti-inflammatory effects of statins, in adipose tissue 
[36] and in the vascular wall [37]. However, this study is the first, to our knowledge, to show that statins 
may have anti-inflammatory effects in benign prostate tissue. With the exception of an inverse association 
between high HDL and acute prostate inflammation, serum lipid levels were not associated with 
histological prostate inflammation, suggesting that cholesterol-independent effects of statins may underlie 
the association with prostate inflammation.  
Our findings should be considered in the context of the strengths and weaknesses of this study. First, 
although on-study biopsies in REDUCE occurred independent of PSA levels or PSA changes, the 
baseline biopsies, which were analyzed in this study, were largely carried out due to elevated PSA levels. 
As such, these results cannot be used to infer the relationship between statin use and histologic prostate 
inflammation in men without a PSA-driven biopsy. In addition, eligibility criteria for REDUCE ensured 
that all men had baseline PSA levels between 2.5 and 10 ng/ml. Thus, these data cannot be used to infer 
the association between statin use and inflammation in men with normal PSA values. In addition, men 
with high-grade intraepithelial neoplasia, atypical small acinar proliferation, or those with a prostate 
volume >80 mL or those who had undergone previous prostate surgery or those who had an International 
Prostate Symptom Score ≥25 or ≥20 while receiving α-blockers were excluded. Although these 
exclusions increase the homogeneity of the sample, they may limit the generalizability of our results. 
Finally, we lacked data for dose and duration of statin use, precluding dose-response analyses. Study 
strengths include the large, multinational population in REDUCE. Moreover, histological inflammation 
was centrally reviewed by a single pathologist using prostate biopsies confirmed to be negative for 
prostate cancer, whereas prior studies evaluated inflammation in benign regions of the prostate adjacent to 
prostate cancer [16, 24]. This enables us to identify risk factors for histological prostate inflammation 
while ruling out inflammation as a response to the tumor. 
To conclude, epidemiologic and laboratory data strongly support an inverse association between statin use 
and risk of advanced prostate cancer, and improving our understanding of the mechanisms contributing to 
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this inverse association will inform advanced prostate cancer prevention efforts [1]. Using baseline data 
from the REDUCE trial, we report that statin use was associated with reduced presence and extent of 
histological prostate inflammation among men with a negative prostate biopsy. The interpretation of these 
findings with respect to prostate cancer risk is somewhat challenging given the inverse association 
between histological inflammation and prostate cancer risk in REDUCE that may be attributable, at least 
in part, to selection bias induced by PSA-driven baseline biopsies [14]. The only study, to our knowledge, 
that avoided this potential source of bias by obtaining PSA-independent biopsies reported a positive 
association between histological prostate inflammation and prostate cancer risk [16]. In the context of that 
study, in addition to a body of work linking inflammation with increased prostate cancer risk [38], our 
findings suggest that reduction of prostate inflammation could contribute to the inverse association 
between statin use and risk of advanced prostate cancer.  
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Table 1: Demographic characteristics of REDUCE participants according to the presence of chronic and 
acute prostate inflammation at baseline  
 Chronic prostatic inflammation Acute prostatic inflammation
 
Absent 
N=1,504  
(23%) 
Present 
N=5,151  
(77%) 
p value 
Absent 
N=5,650  
(85%) 
Present 
N=1,005  
(15%) 
p value 
Age, mean (SD) 62.2 (6.1) 62.8 (6.0) 0.0006 62.8 (6.0) 62.1 (6.1) 0.0002 
Race, n (%)       
   White 1,400 (93) 4,698 (91) 0.021 5,177 (92) 921 (92) 0.989    Non-white 104 (7) 453 (9) 473 (8) 84 (8) 
Region, n (%)       
   N. America 336 (22) 1,562 (30) 
<0.0001
1,496 (26) 402 (40) 
<0.0001   Europe 990 (66) 2,947 (57) 3,405 (60) 532 (53) 
   Other 178 (12) 642 (12) 749 (13) 71 (7) 
BMI (kg/m2), 
median (IQR) 
26.8 (24.8-
29.0) 
26.9 (24.9-
29.4) 0.277 
26.9 (24.9-
29.4) 
26.9 (24.8-
29.3) 0.766 
Diabetes, n (%)       
   No 1,369 (91) 4,726 (92) 0.373 5,174 (92) 921 (92) 0.944    Yes 135 (9) 425 (8) 476 (8) 84 (8) 
Statin use, n (%)       
   No 1,212 (81) 4,226 (82) 0.198 4,632 (82) 806 (80) 0.178    Yes 292 (19) 925 (18) 1,018 (18) 199 (20) 
NSAID use, n 
(%)       
   No 1,075 (71) 3,629 (70) 0.443 4,011 (71) 693 (69) 0.191    Yes 429 (29) 1,522 (30) 1,639 (29) 312 (31) 
Alcohol use, n 
(%)       
   None 360 (24) 1,372 (27) 
0.040 
1,472 (26) 260 (26) 
0.693    Moderate 720 (48) 2,463 (48) 2,692 (48) 491 (49) 
   Heavy 417 (28) 1,292 (25) 1,461 (26) 248 (25) 
Smoking status, 
n (%)       
   Never 698 (46) 2,321 (45) 
0.124 
2,580 (46) 439 (44) 
0.001    Former 604 (40) 2,028 (39) 2,257 (40) 375 (37) 
   Current 202 (13) 802 (16) 813 (14) 191 (19) 
*data for alcohol use was missing for n=31 participants 
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Table 2: Demographic characteristics of REDUCE participants according to statin use 
 Statin use  
 
No 
N=5,438  
(82%) 
Yes 
N=1,217  
(18%) 
p value 
Age, mean (SD) 62.6 (6.0) 63.1 (6.1) 0.005 
Race, n (%)    
   White 4,964 (91) 1,134 (93) 0.031    Non-white 474 (9) 83 (7) 
Region, n (%)    
   N. America 1,274 (23) 624 (51) 
<0.0001    Europe 3,398 (62) 539 (44) 
   Other 766 (14) 54 (4) 
BMI (kg/m2), median (IQR) 26.8 (24.7-29.1) 27.4 (25.4-30.1) 0.0001 
Diabetes, n (%)    
   No 5,063 (93) 1,032 (85) <0.0001    Yes 375 (7) 185 (15) 
NSAID use, n (%)    
   No 4,207 (77) 497 (41) <0.0001    Yes 1,231 (23) 720 (59) 
Alcohol use, n (%)    
   None 1,383 (26) 349 (29) 
0.054    Moderate 2,630 (49) 553 (46) 
   Heavy 1,400 (26) 309 (26) 
Smoking status, n (%)    
   Never 2,546 (47) 473 (39) 
<0.0001    Former 2,052 (38) 580 (48) 
   Current 840 (15) 164 (13) 
*data for alcohol use was missing for n=31 participants 
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Table 3: Odds ratios for associations between serum lipid levels and the presence and extent of baseline chronic prostate inflammation in 
REDUCE  
 Presence of chronic inflammation  Extent of chronic inflammation  
 None  Any  None  Moderate; < 20% of cores  Severe; ≥ 20% of cores  
 n  n OR (95% CI)  n  n OR (95% CI)  n OR (95% CI)  
Total cholesterol              
<200 mg/dl 264  998 1  264  379 1  605 1  
200-239 mg/dl 908  3,055 0.94 (0.80-1.09)  908  1,153 0.92 (0.77-1.10)  1,866 0.95 (0.80-1.12)  
≥240 mg/dl 332  1,098 0.92 (0.76-1.11)  332  406 0.89 (0.71-1.10)  681 0.95 (0.77-1.16)  
p-trend    0.657     0.501   0.854  
LDL              
<130 mg/dl 733  2,591 1  733  969 1  1,583 1  
130-159 mg/dl 424  1,496 1.03 (0.90-1.19)  424  568 1.04 (0.88-1.23)  917 1.05 (0.90-1.22)  
≥160 mg/dl 347  1,064 0.94 (0.80-1.10)  347  401 0.93 (0.78-1.12)  652 0.95 (0.80-1.12)  
p-trend    0.285     0.313   0.374  
HDL              
<40 mg/dl 271  1,053 1  271  404 1  636 1  
40-59 mg/dl 943  3,139 0.89 (0.77-1.04)  943  1,179 0.87 (0.73-1.04)  1,921 0.90 (0.77-1.07)  
≥60 mg/dl 290  959 0.91 (0.75-1.11)  290  355 0.88 (0.70-1.11)  595 0.94 (0.76-1.15)  
p-trend    0.993     0.857   0.848  
Triglyceride              
<150 mg/dl 953  3,326 1  953  1,253 1  2,038 1  
150-199 mg/dl 279  956 1.00 (0.86-1.17)  279  363 1.00 (0.84-1.20)  575 0.99 (0.84-1.17)  
≥200 mg/dl 272  869 0.93 (0.79-1.09)  272  322 0.90 (0.75-1.09)  539 0.94 (0.80-1.12)  
p-trend    0.329     0.276   0.508  
ORs were adjusted for age at baseline (continuous), race (white, non-white), geographic region (North America, Europe, other), BMI (continuous, 
log-transformed), smoking status (never, former, current), statin use (no, yes), and NSAID use (no, yes) 
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Table 4: Odds ratios for associations between serum lipid levels and presence and extent of baseline acute prostate inflammation in REDUCE  
 Presence of acute inflammation  Extent of acute inflammation  
 None  Any  None  Moderate; < 20% of cores  Severe; ≥ 20% of cores  
 n  n OR (95% CI)  n  n OR (95% CI)  n OR (95% CI)  
Total cholesterol              
<200 mg/dl 1,067  195 1  1,067  125 1  67 1  
200-239 mg/dl 3,364  599 1.06 (0.89-1.27)  3,364  398 1.08 (0.87-1.34)  195 1.04 (0.78-1.39)  
≥240 mg/dl 1,219  211 1.09 (0.87-1.35)  1,219  150 1.18 (0.91-1.52)  61 0.96 (0.67-1.39)  
p-trend    0.669     0.313   0.655  
LDL              
<130 mg/dl 2,802  522 1  2,802  352 1  165 1  
130-159 mg/dl 1,645  275 0.97 (0.82-1.15)  1,645  181 0.95 (0.78-1.16)  91 1.00 (0.76-1.32)  
≥160 mg/dl 1,203  208 1.04 (0.86-1.25)  1,203  140 1.04 (0.83-1.29)  67 1.07 (0.78-1.46)  
p-trend    0.556     0.584   0.670  
HDL              
<40 mg/dl 1,105  219 1  1,105  139 1  79 1  
40-59 mg/dl 3,460  622 0.92 (0.78-1.09)  3,460  419 0.97 (0.79-1.19)  196 0.81 (0.62-1.07)  
≥60 mg/dl 1,085  164 0.79 (0.63-0.99)  1,085  115 0.86 (0.66-1.13)  48 0.66 (0.45-0.97)  
p-trend    0.071     0.248   0.120  
Triglyceride              
<150 mg/dl 3,639  640 1  3,639  418 1  215 1  
150-199 mg/dl 1,054  181 1.00 (0.84-1.20)  1,054  126 1.08 (0.87-1.34)  54 0.87 (0.64-1.19)  
≥200 mg/dl 957  184 1.11 (0.92-1.33)  957  129 1.20 (0.97-1.49)  54 0.95 (0.69-1.30)  
p-trend    0.268     0.118   0.884  
ORs were adjusted for age at baseline (continuous), race (white, non-white), geographic region (North America, Europe, other), BMI (continuous, 
log-transformed), smoking status (never, former, current), statin use (no, yes), and NSAID use (no, yes) 
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Table 5: Odds ratios for associations between statin use and presence and extent of baseline prostate inflammation in REDUCE 
 Presence of chronic inflammation  Extent of chronic inflammation  
 None  Any  None  Moderate; < 20% of cores  Severe; ≥ 20% of cores  
 n  n OR (95% CI)  n  n OR (95% CI)  n OR (95% CI)  
Statin use              
No 1,212  4,226 1  1,212  1,592 1  2,582 1  
Yes 292  925 0.81 (0.69-0.95)  292  346 0.82 (0.68-0.99)  570 0.80 (0.68-0.95)  
              
 Presence of acute inflammation  Extent of acute inflammation  
 None  Any  None  Moderate; < 20% of cores  Severe; ≥ 20% of cores  
 n  n OR (95% CI)  n  n OR (95% CI)  n OR (95% CI)  
Statin use              
No 4,632  806 1  4,632  530 1  269 1  
Yes 1,018  199 0.97 (0.81-1.17)  1,018  143 1.11 (0.90-1.38)  54 0.73 (0.53-1.00)  
ORs were adjusted for age at baseline (continuous), race (white, non-white), geographic region (North America, Europe, other), BMI (continuous, 
log-transformed), smoking status (never, former, current), NSAID use (yes, no) 
 
 
